Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer

doi:10.3760/cma.j.cn371439-20201209-00101

Abstract

Abstract:

Objective To investigate the value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting the occurrence of radiation pneumonitis (RP) in patients with esophageal cancer and lung cancer. Methods The clinicopathological data of 28 patients with esophageal and 16 patients with lung cancer undergoing radiotherapy from April 2018 to March 2020 in Hefei Cancer Hospital, Chinese Academy of Sciences were retrospectively analyzed, and the patients were divided into RP group (n=16) and non-RP group (n=28) according to whether RP occurred during and after treatment. The CD4/CD8 ratio and total B lymphocytes before radiotherapy between the two groups, and the CD4/CD8 ratio and total B lymphocytes before and after radiotherapy in the RP group were compared. Receiver operating characteristic curve was used to analyze the value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting RP. Results The CD4/CD8 ratio before radiotherapy in the RP group was significantly lower than that in the non-RP group (0.993±0.179 vs. 1.708±0.170), with a statistically significant difference (t=2.706, P=0.009); the total B lymphocytes in the RP group was significantly lower than that in non-RP group [(4.409±0.823)% vs. (8.153±1.017)%], with a statistically significant difference (t=0.986, P=0.015). The CD4/CD8 ratio in the RP group was lower than that before radiotherapy when RP occurred (0.785±0.167 vs. 0.993±0.179), with no statistically significant difference (t=1.376, P=0.189). The total B lymphocytes in the RP group was lower than that before radiotherapy when RP occurred [(3.487±1.018)% vs. (4.409±0.823)%], with no statistically significant difference (t=0.804, P=0.433). The critical values of CD4/CD8 ratio and total B lymphocytes predicted RP were 0.580 and 0.357, respectively. The areas under the curve (AUC) of CD4/CD8 for predicting RP was 0.802 (95%CI: 0.653-0.932), the sensitivity was 89.29%, and the specificity was 68.75%. The AUC of total B lymphocytes for predicting RP was 0.694 (95%CI: 0.483-0.814), the sensitivity was 85.71%, and the specificity was 50.00%. The AUC of the two combined diagnostic method for RP was 0.834 (95%CI: 0.697-0.932), the sensitivity and specificity were 81.25% and 89.29%. AUC of the two combined tests was significantly higher than that of the single test, with statistically significant differences (Z=1.115, P=0.046; Z=1.992, P=0.026). Conclusion The CD4/CD8 ratio and total B lymphocytes in the RP group are lower than those in the non-RP group. The CD4/CD8 ratio and total B lymphocytes in the serum are of great significance in predicting the occurrence of RP in patients with malignant tumors receiving chest radiotherapy.

Key words: Esophageal neoplasms, Lung neoplasms, CD4/CD8 ratio, B-lymphocytes, Risk assessment, Radiation pneumonitis

Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer[J]. Journal of International Oncology, 2021, 48(9): 523-526.

Figures/Tables 2

References 12

[1]	国家卫生和计划生育委员会统计信息中心, 中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国死因监测数据集2016[M]. 北京: 中国科学技术出版社, 2017: 26.
[2]	陈万青, 李贺. 人群肿瘤监测在癌症防控中的作用[J]. 肿瘤预防与治疗, 2018, 31(1):1-4. DOI: 10.3969/j.issn.1674-0904.2018.01.001. doi: 10.3969/j.issn.1674-0904.2018.01.001
[3]	史志勇, 王娟, 苏铁涛, 等. 肺癌患者发生放射性肺损伤的相关因素[J]. 临床与病理杂志, 2018, 38(7):1451-1456. DOI: 10.3978/j.issn.2095-6959.2018.07.013. doi: 10.3978/j.issn.2095-6959.2018.07.013
[4]	乔红梅, 郑安婕, 宁鹏, 等. 放射性肺炎相关细胞因子预测因素的研究进展[J]. 现代肿瘤医学, 2020, 28(15):2730-2734. DOI: 10.3969/j.issn.1672-4992.2020.15.041. doi: 10.3969/j.issn.1672-4992.2020.15.041
[5]	常晓龙, 文景丽, 郭英华, 等. 食管癌和肺癌患者血清IL-10、MMP-9、TNF-α预测放射性肺炎临床观察[J]. 潍坊医学院学报, 2019, 41(4):283-287. DOI: 10.16846/j.issn.1004-3101.2019.04.013. doi: 10.16846/j.issn.1004-3101.2019.04.013
[6]	Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1341-1346. DOI: 10.1016/0360-3016(95)00060-C. doi: 10.1016/0360-3016(95)00060-C
[7]	徐金明, 王丽. 肺癌放疗患者放射性肺炎发生情况及影响因素探讨[J]. 临床医药文献电子杂志, 2019, 6(64):58. DOI: 10.16281/j.cnki.jocml.2019.64.046. doi: 10.16281/j.cnki.jocml.2019.64.046
[8]	王树斌, 袁飞, 武云, 等. 放射性肺炎与肺癌患者生物学因素关系的研究进展[J]. 癌症进展, 2018, 16(13):1571-1574. DOI: 10.11877/j.issn.1672-1535.2018.16.13.02. doi: 10.11877/j.issn.1672-1535.2018.16.13.02
[9]	Hu Z, Lin D, Yuan J, et al. Over expression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer[J]. Clin Cancer Res, 2005, 11(13):4646-4652. DOI: 10.1158/1078-0432.CCR-04-2013. doi: 10.1158/1078-0432.CCR-04-2013
[10]	叶萍. 肿瘤患者外周血T淋巴细胞亚群的变化及临床价值分析[J]. 现代诊断与治疗, 2019, 30(22):4005-4007.
[11]	Sheng SY, Gu Y, Lu CG, et al. The distribution and function of human memory T cell subsets in lung cancer[J]. Immunol Res, 2017, 65(3):639-650. DOI: 10.1007/s12026-016-8882-y. doi: 10.1007/s12026-016-8882-y pmid: 28101811
[12]	章梁君, 钟锦莎, 钟辉秀, 等. 恶性肿瘤患者外周血淋巴细胞免疫表型检测的临床意义[J]. 国际检验医学杂志, 2015, 36(24):3565-3567. DOI: 10.3969/j.issn.1673-4130.2015.24.024. doi: 10.3969/j.issn.1673-4130.2015.24.024

一般临床特征	RP组 (n=16)	非RP组 (n=28)	χ²值	P值
性别
男	15	21	1.311	0.252
女	1	7
年龄(岁)
≥60	14	24	0.027	0.768
<60	2	4
病种
食管癌	9	19	0.592	0.441
肺癌	7	9
分期
Ⅰ~Ⅱ	5	11	0.284	0.594
Ⅲ~Ⅳ	11	17
放疗剂量(Gy)
<60	4	8	0.065	0.698
≥60	12	20
同步化疗
有	3	4	0.151	0.627
无	13	24
吸烟史
有	10	17	0.013	0.907
无	6	11

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[6]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[7]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[8]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[9]	Cao Xiaohui, Yu Hong, Li Wanhu. Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis [J]. Journal of International Oncology, 2023, 50(2): 107-111.
[10]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81.
[11]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[12]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750.
[13]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[14]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[15]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.